●In 1965, Southwest Synthetic pharmaceutical factory was founded in Yubei District, Chongqing.
●In 1987, Sulphamethazine, Trimethoprim and Sulfamethoxazole passed US FDA site inspection.
●In 1990, Cuntan manufacturing base was constructed in Jiangbei District, Chongqing.
●In 1993, changed the company name as Southwest Synthetic pharmaceutical Corp., Ltd.
●In 1990, Cuntan manufacturing base was constructed in Jiangbei District, Chongqing.
●In 1993, changed the company name as Southwest Synthetic pharmaceutical Corp., Ltd.
●In 1996, Sulfadimidine and Sulfadiazine received COS/CEP.
●In 1996, listed as key pharmaceutical enterprise of China.
●In 1997, listed on Shenzhen Stock Exchange. (Stock code: 000788)
●In 2003, acquired by Founder Group through capital increase investment.
●Till 2004, all products have been GMP certified.
●In 2008, listed as a brand leader export enterprise by Chongqing government..
●In 2008, R&D center was qualified as a national-level technology center.
●In 2009, Southwest Synthetic pharmaceutical Corp., Ltd became the holder of Chongqing Daxin Pharmaceutical Co., Ltd through directional add-issuance.
●Till 2009, 12 products (including Daxin’s products) have been approved by US FDA, including Sulfadiazine, Sulfamethoxazole, Trimethoprim, Sulfamethazine, Sulfamethazine sodium, Nabumetone, Meclizine hydrochloride, Lovastatin, Mycophenolic acid, Tobramycin, Amikacin sulfate, Amikacin.
●In 2010, the construction of PKU International HealtherCare Group Chongqing pharmaceutical manufacturing base in Chongiqng Liangjiang New Area commenced.
●Till 2010, 7 products (including Daxin’s products) have been granted CEP, including Sulfadiazine, Sulfamethoxazole, Trimethoprim, Sulfadimidine, Hydrochlorothiazide, Tobramycin and Tobramycin form I.
●In September 2011, Southwest Synthetic Pharmaceutical Corp., Ltd acquired Beijing Beiyi Pharmaceutical Co., Ltd. through directional add-issuance, in this way, Southwest Synthetic Pharmaceutical Corp., Ltd. expanded its business from pharmaceutical manufacturing to pharmaceutical circulation and built a national sales circulation platform.
●In 2012, the phase I of Chongqing Pharmaceutical Manufacturing Base was completed for debugging and trail operation phase.
●In 2012, we became one of the top 50 of Chinese Medicine Industry of brand competitiveness.
●In 2012, our company was listed in the key enterprises of Improving New Industrialization of Chongqing.
●In January2013, our home-grown anticancer innovative drug have been in phase II、III.
●In November 2013, our company officially changed the name to PKU HealthCare Co., Ltd.